

*AL
CMT*
(C) a second therapeutic agent or a second conjugate comprising a low molecular weight hapten to which said first conjugate binds and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent.

AN
44
46. (New) The composition of claim 1, wherein said first therapeutic agent is doxorubicin.

45
47. (New) The composition of claim 1, wherein said second therapeutic agent is topotecan.

46
48. (New) The composition of claim *47*, wherein said topotecan is conjugated to a low molecular weight hapten.

47
49. (New) The composition of claim *48*, wherein said first therapeutic agent is doxorubicin.

48
50. (New) The composition of claim 1, wherein (C) is a second therapeutic agent.

49
51. (New) The composition of claim 1, wherein (C) is a second conjugate.

50
52. (New) The composition of claim 1, wherein said first conjugate comprises a recognition arm that recognizes said second therapeutic agent.